Lumos Pharma Inc

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. Show More...

  • Website https://www.lumos-pharma.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 4.33 USD
  • Last Updated 06-12-2024
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -10.15 -26.82 -10.08 -11.07 27.81 -12.69 -26.46 -20.7 -12.96 -10.35 -10.35
    Dividends USD
    Payout Ratio % *
    Shares Mil 2.0 1.0 2.0 3.0 3.0 3.0 3.0 3.0 4.0 4.0 4.0
    Book Value Per Share * USD -31.65 7.69 16.03 22.64 64.78 42.67 25.82 29.52 20.83 14.66
    Free Cash Flow Per Share * USD -6.71 -9.44 -9.69 -10.25 31.69 -18.67 -14.79 -13.06 -5.67
    Return on Assets % -75.86 -52.84 -59.95 -62.37 66.66 -17.69 -43.3 -40.49 -34.4 -37.76 -37.76
    Financial Leverage (Average) 1.32 1.64 1.21 1.17 1.12 1.35 1.19 1.14 1.23 1.23
    Return on Equity % -85.27 -81.78 78.49 -20.21 -52.36 -51.21 -40.19 -44.31 -44.31
    Return on Invested Capital % -73.68 -79.04 77.75 -20.1 -52.25 -51.41 -41.44 -45.64 -45.64
    Interest Coverage -354.49 -429.67 -612.71 -939.91 -319.41 -608.33 -858.54 -858.54
    Current Ratio 4.48 4.01 8.01 16.5 9.21 14.03 4.43 7.96 14.36 7.98 7.98
    Quick Ratio 4.19 3.74 7.7 16.3 8.88 13.69 4.27 7.68 13.74 7.73 7.73
    Debt/Equity 0.03 0.07 0.02